Cabot Corporation
boothcheck covers Cabot Corporation (CBT) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed July 25, 2026.
• Cabot earned a 16.3% operating margin on $3.58 billion of trailing revenue while most of its commodity-chemical cohort was losing money at the operating line, with CELANESE (CE) at -7.8% and HUNTSMAN (HUN) at -3.3%. • The fragile piece is Reinforcement Materials, 63% of revenue, sold under contracts the 10-K describes as arrangements ⟦"with certain customers, the typical duration of which is one year"⟧, and this year's reset took that segment's profit down 29% in the March quarter [Source: Q2
Is CBT overvalued? See what's priced in →
358 institutional managers reported holding CBT in 13F filings for the quarter ended 2026-03-31. 44 opened new positions that quarter. Held by BlackRock, Vanguard Group, Wellington Management, among others. On the short side, 3.2M shares were sold short as of the 2026-06-15 count, about 6% of shares outstanding (6.4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CBT has cut its share count 8.3% over the past five years, spending $593.00M on repurchases. It pays a dividend, and has paid one every year in our records (17 and counting), raised 14 years straight; the current rate is $1.76 a share annually. Cash returned over the past three years: $260.00M in dividends and $491.00M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at CBT over the trailing three years. Absence is a fact about the company, not a signal. 19 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CBT's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-09 | +1.8% | +0.2% |
| 2023-11-23 | +5.5% | -4.9% |
| 2024-02-09 | +5.7% | +16.9% |
| 2024-05-10 | +7.3% | -6.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CBT's latest 8-K filings: 2026-08-21 (items 8.01, 9.01); 2026-08-14 (items 8.01, 9.01); 2026-08-03 (items 2.02, 9.01); 2026-07-30 (items 5.02, 7.01, 9.01); 2026-05-14 (items 1.01, 1.02, 2.03, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.